Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: New targets for novel therapies for fatty liver disease and insulin resistance

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 310, Issue 11, 2016, Pages G1102-G1117

  Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Gaucher disease; Glycosphingolipids; Insulin resistance; NAFLD; NASH; glucosylceramide

Indexed keywords

ADIPONECTIN; CERAMIDE; FINGOLIMOD; GLYCOSPHINGOLIPID; IMINOSUGAR; INSULIN; OBETICHOLIC ACID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; DIABETES MELLITUS; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CANCER; MACROPHAGE ACTIVATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; FATTY LIVER; GENETICS; METABOLISM; SECOND MESSENGER;

ANIMALS; CERAMIDES; FATTY LIVER; GAUCHER DISEASE; HUMANS; INSULIN RESISTANCE; SECOND MESSENGER SYSTEMS; SPHINGOMYELINS;

EID: 84984604172     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00095.2016     Document Type: Review

References (194)

1. Adar T, Ben-Ami R, Elstein D, Zimran A, Berliner S, Yedgar S, Barshtein G. Aggregation of red blood cells in patients with Gaucher disease. Br J Haematol 134: 432–437, 2006.
2. Adar T, Ben Ya’acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M, Wong V, Muller B, Rawlin G, Ilan Y. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol 167: 252–260, 2012.
3. Adiseshaiah PP, Clogston JD, McLeland CB, Rodriguez J, Potter TM, Neun BW, Skoczen SL, Shanmugavelandy SS, Kester M, Stern ST, McNeil SE. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett 337: 254–265, 2013.
4. Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS. Glycosphingolipids and insulin resistance. Adv Exp Med Biol 721: 99–119, 2011.
5. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O’Rahilly S, Overkleeft HS. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56: 1341–1349, 2007.
6. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 82: 5715–5724, 2008.
7. Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. Clin Neurol Neurosurg 119: 17–20, 2014.
8. Andrade-Oliveira V, Camara NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res 2015: 681612, 2015.
9. Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, Bedossa P, Kontush A, Clement K, Dugail I, Tordjman J. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol 62: 905–912, 2015.
10. Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016: 8606878, 2016.
11. Arish M, Husein A, Kashif M, Saleem M, Akhter Y, Rub A. Sphingosine-1-phosphate signaling: unraveling its role as a drug target against infectious diseases. Drug Discov Today 21: 133–142, 2016.
12. Astudillo L, Therville N, Colacios C, Segui B, Andrieu-Abadie N, Levade T. Glucosylceramidases and malignancies in mammals. Biochimie 125: 267–280, 2016.
13. Ayto R, Hughes DA. Gaucher disease and myeloma. Crit Rev Oncog 18: 247–268, 2013.
14. Balreira A, Cavallari M, Sa Miranda MC, Arosa FA. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-Bepoxide and iNKT cell responsiveness. Immunobiology 215: 505–513, 2010.
15. Balreira A, Lacerda L, Miranda CS, Arosa FA. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHCclass II: monocytes from Gaucher disease patients as a model. Br J Haematol 129: 667–676, 2005.
16. Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, Martini C, Gioulis M, Pittis MG, Capus L. Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 61: 99–101, 2003.
17. Bertram HC, Eldibany M, Padgett J, Dragon LH. Splenic lymphoma arising in a patient with Gaucher disease. A case report and review of the literature. Arch Pathol Lab Med 127: e242–e245, 2003.
18. Bhabak KP, Arenz C. Novel drugs targeting sphingolipid metabolism. Handb Exp Pharmacol 187–196, 2013.
19. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 31: 337–349, 2008.
20. Bijl N, Scheij S, Houten S, Boot RG, Groen AK, Aerts JM. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells. J Pharmacol Exp Ther 326: 849–855, 2008.
21. Bijl N, Sokolovic M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50: 1431–1441, 2009.
22. Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637–645, 2009.
23. Bikman BT. A role for sphingolipids in the pathophysiology of obesityinduced inflammation. Cell Mol Life Sci 69: 2135–2146, 2012.
24. Boden G. Ceramide: a contributor to insulin resistance or an innocent bystander? Diabetologia 51: 1095–1096, 2008.
25. Bohm P, Kunz W, Horny HP, Einsele H. Adult Gaucher disease in association with primary malignant bone tumors. Cancer 91: 457–462, 2001.
26. Brands M, van Raalte DH, Joao Ferraz M, Sauerwein HP, Verhoeven AJ, Aerts JM, Diamant M, Serlie MJ. No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoidinduced insulin resistance in healthy men. J Clin Endocrinol Metab 98: 1219–1225, 2013.
27. Braudeau C, Graveleau J, Rimbert M, Neel A, Hamidou M, Grosbois B, Besancon A, Giraudet S, Terrien C, Josien R, Masseau A. Altered innate function of plasmacytoid dendritic cells restored by enzyme replacement therapy in Gaucher disease. Blood Cells Mol Dis 50: 281–288, 2013.
28. Brown MV, Compton SA, Milburn MV, Lawton KA, Cheatham B. Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. Obesity (Silver Spring) 21: E561–E570, 2013.
29. Caballero F, Fernandez A, Matias N, Martinez L, Fucho R, Elena M, Caballeria J, Morales A, Fernandez-Checa JC, Garcia-Ruiz C. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem 285: 18528–18536, 2010.
30. Candido K, Soufi H, Bandyopadhyay M, Dasgupta S. Therapeutic impact of sphingosine 1-phosphate receptor signaling in multiple sclerosis. Mini Rev Med Chem 16: 547–554, 2016.
31. Carr RM, Peralta G, Yin X, Ahima RS. Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice. PLoS One 9: e97118, 2014.
32. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 15: 585–594, 2012.
33. Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV. Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49, Suppl 5: S72–S84, 2009.
34. Cheng L, Chen YZ, Peng Y, Yi N, Gu XS, Jin Y, Bai XM. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells. Tumour Biol 36: 5763–5771, 2015.
35. Chung RW, Kamili A, Tandy S, Weir JM, Gaire R, Wong G, Meikle PJ, Cohn JS, Rye KA. Dietary sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol absorption in high-fat-fed mice. PLoS One 8: e55949, 2013.
36. Clugston RD, Jiang H, Lee MX, Piantedosi R, Yuen JJ, Ramakrishnan R, Lewis MJ, Gottesman ME, Huang LS, Goldberg IJ, Berk PD, Blaner WS. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J Lipid Res 52: 2021–2031, 2011.
37. Cochran G, Hardy J, Harpending H. Natural history of Ashkenazi intelligence. J Biosoc Sci 38: 659–693, 2006.
38. Corssmit EP, Hollak CE, Endert E, van Oers MH, Sauerwein HP, Romijn JA. Increased basal glucose production in type 1 Gaucher’s disease. J Clin Endocrinol Metab 80: 2653–2657, 1995.
39. de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JE, de Groot E, Mannens MM, Bikker H, Aerts JM, Kastelein JJ, Hollak CE. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204: 267–272, 2009.
40. de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JE, de Groot E, Mannens MM, Bikker H, Aerts JM, Kastelein JJ, Hollak CE. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204: 267–272, 2009.
41. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36: 53–58, 2006.
42. Delgado A, Fabrias G, Bedia C, Casas J, Abad JL. Sphingolipid modulation: a strategy for cancer therapy. Anticancer Agents Med Chem 12: 285–302, 2012.
43. Depner CM, Traber MG, Bobe G, Kensicki E, Bohren KM, Milne G, Jump DB. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR Bfl/A1 mice. PLoS One 8: e83756, 2013.
44. Dimanche-Boitrel MT, Rebillard A. Sphingolipids and response to chemotherapy. Hand Exp Pharmacol 216: 73–91, 2013.
45. Doneda D, Lopes AL, Teixeira BC, Mittelstadt SD, Moulin CC, Schwartz IV. Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy. Clin Nutr 34: 727–731, 2015.
46. Doneda D, Netto CB, Moulin CC, Schwartz IV. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond) 10: 34, 2013.
47. Eisinger K, Krautbauer S, Hebel T, Schmitz G, Aslanidis C, Liebisch G, Buechler C. Lipidomic analysis of the liver from high-fat diet induced obese mice identifies changes in multiple lipid classes. Exp Mol Pathol 97: 37–43, 2014.
48. Fernandez A, Matias N, Fucho R, Ribas V, Von Montfort C, Nuno N, Baulies A, Martinez L, Tarrats N, Mari M, Colell A, Morales A, Dubuquoy L, Mathurin P, Bataller R, Caballeria J, Elena M, Balsinde J, Kaplowitz N, Garcia-Ruiz C, Fernandez-Checa JC. ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol 59: 805–813, 2013.
49. Fuller M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis 9: 113, 2010.
50. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70: 2277–2283, 2008.
51. Garcia-Ruiz C, Colell A, Mari M, Morales A, Calvo M, Enrich C, Fernandez-Checa JC. Defective TNF-α-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest 111: 197–208, 2003.
52. Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernandez-Checa JC. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J Hepatol 62: 219–233, 2015.
53. Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernandez-Checa JC. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J Hepatol 62: 219–233, 2015.
54. Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Glycosphingolipids and cell death: one aim, many ways. Apoptosis 20: 607–620, 2015.
55. Garris CS, Blaho VA, Hla T, Han MH. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology 142: 347–353, 2014.
56. Gatt S, Dagan A. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids. Chem Phys Lipids 165: 462–474, 2012.
57. Ghasemi R, Dargahi L, Ahmadiani A. Integrated sphingosine-1 phosphate signaling in the central nervous system: From physiological equilibrium to pathological damage. Pharmacol Res 104: 156–164, 2016.
58. Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, Groener JE. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389: 109–113, 2008.
59. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65: 1353–1357, 2008.
60. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 41: 937–940, 2004.
61. Gornati R, Berra B, Montorfano G, Martini C, Ciana G, Ferrari P, Romano M, Bembi B. Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. J Inherit Metab Dis 25: 47–55, 2002.
62. Grammatikos G, Ferreiros N, Bon D, Schwalm S, Dietz J, Berkowski C, Fitting D, Herrmann E, Zeuzem S, Sarrazin C, Pfeilschifter J. Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection. Hepatology 61: 812–822, 2015.
63. Grammatikos G, Muhle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J. Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochim Biophys Acta 1841: 1012–1020, 2014.
64. Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res 51: 50–62, 2012.
65. Guimaraes LL, Toledo MS, Ferreira FA, Straus AH, Takahashi HK. Structural diversity and biological significance of glycosphingolipids in pathogenic and opportunistic fungi. Front Cell Infect Microbiol 4: 138, 2014.
66. Gulbins E, Palmada M, Reichel M, Luth A, Bohmer C, Amato D, Muller CP, Tischbirek CH, Groemer TW, Tabatabai G, Becker KA, Tripal P, Staedtler S, Ackermann TF, van Brederode J, Alzheimer C, Weller M, Lang UE, Kleuser B, Grassme H, Kornhuber J. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med 19: 934–938, 2013.
67. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 1758: 2016–2026, 2006.
68. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36: 426–428, 2006.
69. Hartmann D, Lucks J, Fuchs S, Schiffmann S, Schreiber Y, Ferreiros N, Merkens J, Marschalek R, Geisslinger G, Grosch S. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol 44: 620–628, 2012.
70. Hartmann D, Wegner MS, Wanger RA, Ferreiros N, Schreiber Y, Lucks J, Schiffmann S, Geisslinger G, Grosch S. The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS. Int J Biochem Cell Biol 45: 1195–1203, 2013.
71. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337–343, 2009.
72. Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab 16: 420–434, 2012.
73. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 121: 1858–1870, 2011.
74. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55–63, 2011.
75. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29: 381–402, 2008.
76. Huwiler A, Pfeilschifter J. Lipids as targets for novel anti-inflammatory therapies. Pharmacol Ther 124: 96–112, 2009.
77. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75: 1893–1900, 2008.
78. Hyysalo J, Gopalacharyulu P, Bian H, Hyotylainen T, Leivonen M, Jaser N, Juuti A, Honka MJ, Nuutila P, Olkkonen VM, Oresic M, Yki-Jarvinen H. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 63: 312–322, 2014.
79. Ilan Y, Elstein D, Zimran A. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol Cell Biol 87: 514–524, 2009.
80. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, Wu HY, Weiner HL. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 107: 9765–9770, 2010.
81. Inokuchi J. Insulin resistance as a membrane microdomain disorder. Yakugaku Zasshi 127: 579–586, 2007.
82. Itokawa K, Tamura N, Kawai N, Shimazu K, Ishii K. Parkinsonism in type I Gaucher’s disease. Intern Med 45: 1165–1167, 2006.
83. Jariwala SP, Fodeman J, Hudes G, Ahuja K, Rosenstreich D. Functional antibody deficiency in a patient with type I Gaucher disease. J Inh Metab Dis 31, Suppl 2: S267–S270, 2008.
84. Jennemann R, Rothermel U, Wang S, Sandhoff R, Kaden S, Out R, van Berkel TJ, Aerts JM, Ghauharali K, Sticht C, Grone HJ. Hepatic glycosphingolipid deficiency and liver function in mice. Hepatology 51: 1799–1809, 2010.
85. Jessup CF, Bonder CS, Pitson SM, Coates PT. The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function. Endocr Metab Immune Disord Drug Targets 11: 262–272, 2011.
86. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125: 386–402, 2015.
87. Jorns A, Rath KJ, Terbish T, Arndt T, Meyer Zu Vilsendorf A, Wedekind D, Hedrich HJ, Lenzen S. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW1AR1-iddm rat despite immune cell activation. Endocrinology 151: 3555–3565, 2010.
88. Kannai R, Elstein D, Weiler-Razell D, Zimran A. The selective advantage of Gaucher’s disease: TB or not TB? Isr J Med Sci 30: 911–912, 1994.
89. Karaahmet F, Akinci H, Ayte R, Hamamci M, Coskun Y, Yuksel I. Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn’s disease. J Crohns Colitis 7: e404, 2013.
90. Kendall MR, Hupfeld CJ. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes Metab 10: 802–805, 2008.
91. Kurek K, Wiesiolek-Kurek P, Piotrowska DM, Lukaszuk B, Chabowski A, Zendzianendzian-Piotrowska M. Inhibition of ceramide de novo synthesis with myriocin affects lipid metabolism in the liver of rats with streptozotocin-induced type 1 diabetes. Biomed Res Int 2014: 980815, 2014.
92. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 64: 2270–2284, 2007.
93. Langeveld M, Aerts JM. Glycosphingolipids and insulin resistance. Prog Lipid Res 48: 196–205, 2009.
94. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 40: 428–432, 2008.
95. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 93: 845–851, 2008.
96. Langeveld M, van den Berg SA, Bijl N, Bijland S, van Roomen CP, Houben-Weerts JH, Ottenhoff R, Houten SM, van Dijk KW, Romijn JA, Groen AK, Aerts JM, Voshol PJ. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation. Metabolism 61: 99–107, 2012.
97. Li Y, Dong J, Ding T, Kuo MS, Cao G, Jiang XC, Li Z. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramidemediated peroxisome proliferator-activated receptor gamma2 suppression. Aterioscler Thromb Vasc Biol 33: 1513–1520, 2013.
98. Liangpunsakul S, Rahmini Y, Ross RA, Zhao Z, Xu Y, Crabb DW. Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanolfed mice. Am J Physiol Gastrointest Liver Physiol 302: G515–G523, 2012.
99. Lizarazo D, Zabala V, Tong M, Longato L, de la Monte SM. Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis. J Gastroenterol Hepatol 28: 1660–1668, 2013.
100. Lombardo E, van Roomen CP, van Puijvelde GH, Ottenhoff R, van Eijk M, Aten J, Kuiper J, Overkleeft HS, Groen AK, Verhoeven AJ, Aerts JM, Bietrix F. Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism. PLoS One 7: e38520, 2012.
101. Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis 16: 715–729, 2009.
102. Magkos F, Su X, Bradley D, Fabbrini E, Conte C, Eagon JC, Varela JE, Brunt EM, Patterson BW, Klein S. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142: 1444–1446.e2, 2012.
103. Manti S, Romano C, Chirico V, Filippelli M, Cuppari C, Loddo I, Salpietro C, Arrigo T. Nonalcoholic fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic “mal-programming.” Hepat Mon 14: e17641, 2014.
104. Margalit M, Shalev Z, Pappo O, Sklair-Levy M, Alper R, Gomori M, Engelhardt D, Rabbani E, Ilan Y. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 319: 105–110, 2006.
105. Margalit MZL, Hemed N, Elstein D, Zimran A, Ilan Y. Glucocerebroside induces altered anti hepatitis C immunity in patients with Gaucher’s disease. Hepatology 38, Suppl 1: 490A, 2003.
106. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab 4: 185–198, 2006.
107. Mari M, Colell A, Morales A, Paneda C, Varela-Nieto I, Garcia-Ruiz C, Fernandez-Checa JC. Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis. J Clin Invest 113: 895–904, 2004.
108. Mari M, Fernandez-Checa JC. Sphingolipid signalling and liver diseases. Liver Int 27: 440–450, 2007.
109. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 147: 577–594.e1, 2014.
110. Martinez-Una M, Varela-Rey M, Cano A, Fernandez-Ares L, Beraza N, Aurrekoetxea I, Martinez-Arranz I, Garcia-Rodriguez JL, Buque X, Mestre D, Luka Z, Wagner C, Alonso C, Finnell RH, Lu SC, Martinez-Chantar ML, Aspichueta P, Mato JM. Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology 58: 1296–1305, 2013.
111. Martinez L, Torres S, Baulies A, Alarcon-Vila C, Elena M, Fabrias G, Casas J, Caballeria J, Fernandez-Checa JC, Garcia-Ruiz C. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaining de novo ceramide synthesis. Oncotarget 6: 41479–41496, 2015.
112. Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr 28: 273–293, 2008.
113. McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P, Lin E, Glaser S, Alpini G, Meng F. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med 18: 197–207, 2014.
114. Mehta A. Gaucher disease: unmet treatment needs. Acta Paediatr Suppl 97: 83–87, 2008.
115. Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res 126: 257–279, 2015.
116. Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 5: 177, 2014.
117. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10: 656–665, 2013.
118. Micheva I, Marinakis T, Repa C, Kouraklis-Symeonidis A, Vlacha V, Anagnostopoulos N, Zoumbos N, Symeonidis A. Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cells Mol Dis 36: 298–307, 2006.
119. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, Albert M, Varma V, Harris G, Schneider EB, Rabins PV, Bandeen-Roche K, Lyketsos CG, Carlson MC. Serum ceramides increase the risk of Alzheimer disease: the Women’s Health and Aging Study II. Neurology 79: 633–641, 2012.
120. Mizrahi M, Shabat Y, Ben Ya’acov A, Lalazar G, Adar T, Wong V, Muller B, Rawlin G, Ilan Y. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 5: 141–150, 2012.
121. Moles A, Tarrats N, Morales A, Dominguez M, Bataller R, Caballeria J, Garcia-Ruiz C, Fernandez-Checa JC, Mari M. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 177: 1214–1224, 2010.
122. Moraitou M, Dimitriou E, Dekker N, Monopolis I, Aerts J, Michelakakis H. Gaucher disease: plasmalogen levels in relation to primary lipid abnormalities and oxidative stress. Blood Cells Mol Dis 53: 30–33, 2014.
123. Morino-Koga S, Yano S, Kondo T, Shimauchi Y, Matsuyama S, Okamoto Y, Suico MA, Koga T, Sato T, Shuto T, Arima H, Wada I, Araki E, Kai H. Insulin receptor activation through its accumulation in lipid rafts by mild electrical stress. J Cell Physiol 228: 439–446, 2013.
124. Mucci JM, Scian R, De Francesco PN, Garcia FS, Ceci R, Fossati CA, Delpino MV, Rozenfeld PA. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-Αα. Gene 509: 51–59, 2012.
125. Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 280: 5317–5336, 2013.
126. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385: 956–965, 2015.
127. Niebergall LJ, Jacobs RL, Chaba T, Vance DE. Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis. Biochim Biophys Acta 1811: 1177–1185, 2011.
128. Nietupski JB, Pacheco JJ, Chuang WL, Maratea K, Li L, Foley J, Ashe KM, Cooper CG, Aerts JM, Copeland DP, Scheule RK, Cheng SH, Marshall J. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol Genet Metab 105: 621–628, 2012.
129. Noguchi M, Suzuki T, Kabayama K, Takahashi H, Chiba H, Shiratori M, Abe S, Watanabe A, Satoh M, Hasegawa T, Tagami S, Ishii A, Saitoh M, Kaneko M, Iseki K, Igarashi Y, Inokuchi J. GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Sci 98: 1625–1632, 2007.
130. Nojima H, Freeman CM, Gulbins E, Lentsch AB. Sphingolipids in liver injury, repair and regeneration. Biol Chem 396: 633–643, 2015.
131. Osawa Y, Seki E, Kodama Y, Suetsugu A, Miura K, Adachi M, Ito H, Shiratori Y, Banno Y, Olefsky JM, Nagaki M, Moriwaki H, Brenner DA, Seishima M. Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMPactivated protein kinase suppression. FASEB J 25: 1133–1144, 2011.
132. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 23: 365–371, 2012.
133. Pandey MK, Jabre NA, Xu YH, Zhang W, Setchell KD, Grabowski GA. Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol Genet Metab 111: 163–171, 2014.
134. Pandey MK, Rani R, Zhang W, Setchell K, Grabowski GA. Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab 106: 310–322, 2012.
135. Park JW, Park WJ, Kuperman Y, Boura-Halfon S, Pewzner-Jung Y, Futerman AH. Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. Hepatology 57: 525–532, 2013.
136. Perez-Calvo J, Bernal M, Giraldo P, Torralba MA, Civeira F, Giralt M, Pocovi M. Co-morbidity in Gaucher’s disease results of a nationwide enquiry in Spain. Eur J Med Res 5: 231–235, 2000.
137. Pewzner-Jung Y, Brenner O, Braun S, Laviad EL, Ben-Dor S, Feldmesser E, Horn-Saban S, Amann-Zalcenstein D, Raanan C, Berkutzki T, Erez-Roman R, Ben-David O, Levy M, Holzman D, Park H, Nyska A, Merrill AH Jr, Futerman AH. A critical role for ceramide synthase 2 in liver homeostasis: II. Insights into molecular changes leading to hepatopathy. J Biol Chem 285: 10911–10923, 2010.
138. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081–1090, 2007.
139. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50: 1827–1838, 2009.
140. Purohit V, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, Kaplowitz N, Kharbanda KK, Liu QY, Lu SC, McClain CJ, Swanson C, Zakhari S. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 86: 14–24, 2007.
141. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA, Russell DW, McDonald JG, Subramaniam S, Fahy E, Dennis EA. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 51: 3299–3305, 2010.
142. Quillin RC 3rd, Wilson GC, Nojima H, Freeman CM, Wang J, Schuster RM, Blanchard JA, Edwards MJ, Gandhi CR, Gulbins E, Lentsch AB. Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice. Hepatol Res 45: 305–314, 2015.
143. Ramirez T, Longato L, Dostalek M, Tong M, Wands JR, de la Monte SM. Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol 48: 39–52, 2013.
144. Rogaeva E, Hardy J. Gaucher and Parkinson diseases: unexpectedly related. Neurology 70: 2272–2273, 2008.
145. Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H, Manns MP. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 19: 828–833, 2006.
146. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105: 4569–4572, 2005.
147. Russo SB, Baicu CF, Van Laer A, Geng T, Kasiganesan H, Zile MR, Cowart LA. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest 122: 3919–3930, 2012.
148. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NFkappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 24: 835–845, 2012.
149. Samad F, Badeanlou L, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol 721: 67–86, 2011.
150. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55: 2579–2587, 2006.
151. Schengrund CL. Gangliosides: glycosphingolipids essential for normal neural development and function. Trends Biochem Sci 40: 397–406, 2015.
152. Schwalm S, Pfeilschifter J, Huwiler A. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol 114: 44–49, 2014.
153. Sharma AK. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opin Ther Pat 21: 807–812, 2011.
154. Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc 124: 46–60, 2013.
155. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 72: 219–224, 1993.
156. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 116: 1793–1801, 2006.
157. Shvidel L, Hurwitz N, Shtalrid M, Zur S, Oliver O, Berrebi A. Complex IgA gammopathy in Gaucher’s disease. Leuk Lymphoma 20: 165–168, 1995.
158. Sillence DJ. Glucosylceramide modulates endolysosomal pH in Gaucher disease. Mol Genet Metab 109: 194–200, 2013.
159. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31–39, 2000.
160. Soeters MR, Sauerwein HP, Dubbelhuis PF, Groener JE, Ackermans MT, Fliers E, Aerts JM, Serlie MJ. Muscle adaptation to short-term fasting in healthy lean humans. J Clin Endocrinol Metab 93: 2900–2903, 2008.
161. Sotiropoulos C, Theodorou G, Repa C, Marinakis T, Verigou E, Solomou E, Karakantza M, Symeonidis A. Severe impairment of regulatory T-cells and Th1-lymphocyte polarization in patients with Gaucher disease. JIMD Rep 18: 107–115, 2015.
162. Sprecher-Levy H, Orr-Urtreger A, Lonai P, Horowitz M. Murine prosaposin: expression in the reproductive system of a gene implicated in human genetic diseases. Cell Mol Biol (Noisy-le-grand) 39: 287–299, 1993.
163. Stratford S, Hoehn KL, Liu F, Summers SA. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279: 36608–36615, 2004.
164. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 56: 704–713, 2012.
165. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21: 33–40, 2010.
166. Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A, Saito M, Ohtsuka Y, Sakaue S, Igarashi Y. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 277: 3085–3092, 2002.
167. Tatematsu K, Tanaka Y, Sugiyama M, Sudoh M, Mizokami M. Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. J Med Virol 83: 587–593, 2011.
168. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79: 104–109, 2003.
169. Tong M, Longato L, Ramirez T, Zabala V, Wands JR, de la Monte SM. Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin. Int J Exp Pathol 95: 49–63, 2014.
170. Trajkovic-Bodennec S, Bodennec J, Futerman AH. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells Mol Dis 33: 77–82, 2004.
171. Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight. Mol Genet Metab 96: 50–51, 2009.
172. van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, Dubbelhuis PF, Seeman I, Ghauharali-van der Vlugt K, Overkleeft HS, Arbeeny C, Groen AK, Aerts JM. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 4: e4723, 2009.
173. Van Sluijters DA, Van Woerkom GM, Aerts JM, Meijer AJ. Sphingomyelinase treatment of rat hepatocytes inhibits cell-swelling-stimulated glycogen synthesis by causing cell shrinkage. Eur J Biochem 266: 653–659, 1999.
174. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS 40. Nat Cell Biol 9: 316–323, 2007.
175. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Terce F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell Microbiol 10: 606–617, 2008.
176. Watt MJ, Barnett AC, Bruce CR, Schenk S, Horowitz JF, Hoy AJ. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 55: 2741–2746, 2012.
177. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, vom Dahl S. Life expectancy in Gaucher disease type 1. Am J Hematol 83: 896–900, 2008.
178. Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, van Eijk M, Ottenhoff R, Bijl N, Ghauharali K, Song H, O’Shea TJ, Liu H, Yew N, Copeland D, van den Berg RJ, van der Marel GA, Overkleeft HS, Aerts JM. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem 53: 689–698, 2010.
179. Worgall TS. Sphingolipid synthetic pathways are major regulators of lipid homeostasis. Adv Exp Med Biol 721: 139–148, 2011.
180. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH Jr, Reid LM, Lemon SM. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20: 927–935, 2014.
181. Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol 20: 14430–14441, 2014.
182. Yunoki K, Renaguli M, Kinoshita M, Matsuyama H, Mawatari S, Fujino T, Kodama Y, Sugiyama M, Ohnishi M. Dietary sphingolipids ameliorate disorders of lipid metabolism in Zucker fatty rats. J Agric Food Chem 58: 7030–7035, 2010.
183. Zeidan YH, Jenkins RW, Hannun YA. Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 181: 335–350, 2008.
184. Zhang B, Xue C, Hu X, Xu J, Li Z, Wang J, Yanagita T, Xue Y, Wang Y. Dietary sea cucumber cerebroside alleviates orotic acidinduced excess hepatic adipopexis in rats. Lipids Health Dis 11: 48, 2012.
185. Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, Pacheco J, Piepenhagen P, Copeland D, Arbeeny C, Shayman JA, Aerts JM, Jiang C, Cheng SH, Yew NS. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50: 85–93, 2009.
186. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56: 1210–1218, 2007.
187. Zhu J, Wang Y, Yu Y, Wang Z, Zhu T, Xu X, Liu H, Hawke D, Zhou D, Li Y. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues. Liver Int 34: 147–160, 2014.
188. Ziegler AN, Levison SW, Wood TL. Insulin and IGF receptor signalling in neural-stem-cell homeostasis. Nat Rev Endocrinol 11: 161–170, 2015.
189. Zigmond ELG, Pappo O, Zangen S, Levy Sklair M, Hemed N, Rabbani E, Itamar R, Ilan Y, Margalit M. Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: a phase I/II clinical study. Hepatology 44. 180A, 2006.
190. Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z, Zolotarov L, Friedman D, Alper R, Ilan Y. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphocyte plasticity in murine models of immune-mediated disorders. Gut 56: 82–89, 2007.
191. Zigmond E, Tayer-Shifman O, Lalazar G, Ben Ya’acov A, Weksler-Zangen S, Shasha D, Sklair-Levy M, Zolotarov L, Shalev Z, Kalman R, Ziv E, Raz I, Ilan Y. β-Glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. J Inflamm Res 7: 151–158, 2014.
192. Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, Raz I, Ilan Y. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 296: E72–E78, 2009.
193. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34: 197–200, 2005.
194. Zimran A, Neudorfer O, Elstein D. The glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 352: 728–731; author reply 728–731, 2005.